|
Gene: IKZF5 |
Gene summary for IKZF5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | IKZF5 | Gene ID | 64376 |
Gene name | IKAROS family zinc finger 5 | |
Gene Alias | PEGASUS | |
Cytomap | 10q26.13 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9H5V7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64376 | IKZF5 | HCC1_Meng | Human | Liver | HCC | 5.26e-13 | -4.42e-02 | 0.0246 |
64376 | IKZF5 | HCC2_Meng | Human | Liver | HCC | 3.17e-07 | -3.54e-03 | 0.0107 |
64376 | IKZF5 | HCC1 | Human | Liver | HCC | 4.69e-02 | 2.41e+00 | 0.5336 |
64376 | IKZF5 | HCC2 | Human | Liver | HCC | 4.09e-05 | 2.33e+00 | 0.5341 |
64376 | IKZF5 | S016 | Human | Liver | HCC | 2.16e-02 | 1.99e-01 | 0.2243 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | |
Endometrium | AEH | |
Endometrium | EEC | |
Prostate | BPH | |
Prostate | Tumor |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IKZF5 | SNV | Missense_Mutation | c.659N>G | p.Pro220Arg | p.P220R | Q9H5V7 | protein_coding | tolerated(0.21) | possibly_damaging(0.505) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
IKZF5 | SNV | Missense_Mutation | novel | c.980N>C | p.Val327Ala | p.V327A | Q9H5V7 | protein_coding | tolerated(0.51) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IKZF5 | SNV | Missense_Mutation | rs755581220 | c.1069G>T | p.Val357Phe | p.V357F | Q9H5V7 | protein_coding | tolerated(0.32) | benign(0.037) | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
IKZF5 | SNV | Missense_Mutation | novel | c.1000C>G | p.Pro334Ala | p.P334A | Q9H5V7 | protein_coding | tolerated(0.84) | benign(0.003) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
IKZF5 | SNV | Missense_Mutation | novel | c.751N>A | p.Pro251Thr | p.P251T | Q9H5V7 | protein_coding | deleterious(0.01) | benign(0.272) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
IKZF5 | insertion | Nonsense_Mutation | novel | c.821_822insTTGTTTATTCAATGTCTAAACACATGTCAGTTTTCCACTGGATTTT | p.Pro275CysfsTer6 | p.P275Cfs*6 | Q9H5V7 | protein_coding | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
IKZF5 | SNV | Missense_Mutation | novel | c.1132C>A | p.Leu378Ile | p.L378I | Q9H5V7 | protein_coding | deleterious(0.04) | probably_damaging(0.987) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
IKZF5 | SNV | Missense_Mutation | c.703N>T | p.Pro235Ser | p.P235S | Q9H5V7 | protein_coding | tolerated(0.21) | benign(0) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
IKZF5 | SNV | Missense_Mutation | rs745563418 | c.470N>A | p.Arg157Gln | p.R157Q | Q9H5V7 | protein_coding | tolerated(0.1) | probably_damaging(0.992) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IKZF5 | SNV | Missense_Mutation | c.1198N>G | p.Lys400Glu | p.K400E | Q9H5V7 | protein_coding | tolerated(0.17) | benign(0.118) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |